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Blood pressure thresholds in pregnancy for identifying 
maternal and infant risk: a secondary analysis of 
Community-Level Interventions for Pre-eclampsia (CLIP) 
trial data
Jeffrey N Bone*, Laura A Magee*, Joel Singer, Hannah Nathan, Rahat N Qureshi, Charfudin Sacoor, Esperança Sevene, Andrew Shennan, 
Mrutyunjaya B Bellad, Shivaprasad S Goudar, Ashalata A Mallapur, Khátia Munguambe, Marianne Vidler, Zulfiqar A Bhutta, Peter von Dadelszen, 
on behalf of the CLIP study group†
Summary
Background Blood pressure measurement is a marker of antenatal care quality. In well resourced settings, lower blood 
pressure cutoffs for hypertension are associated with adverse pregnancy outcomes. We aimed to study the associations 
between blood pressure thresholds and adverse outcomes and the diagnostic test properties of these blood pressure 
cutoffs in low-resource settings.
Methods We did a secondary analysis of data from 22 intervention clusters in the Community-Level Interventions for 
Pre-eclampsia (CLIP) cluster randomised trials (NCT01911494) in India (n=6), Mozambique (n=6), and Pakistan 
(n=10). We included pregnant women aged 15–49 years (12–49 years in Mozambique), identified in their community 
by trained community health workers, who had data on blood pressure measurements and outcomes. The trial was 
unmasked. Maximum blood pressure was categorised as: normal blood pressure (systolic blood pressure [sBP] 
<120 mm Hg and diastolic blood pressure [dBP] <80 mm Hg), elevated blood pressure (sBP 120–129 mm Hg and 
dBP <80 mm Hg), stage 1 hypertension (sBP 130–139 mm Hg or dBP 80–89 mm Hg, or both), non-severe stage 2 
hypertension (sBP 140–159 mm Hg or dBP 90–109 mm Hg, or both), or severe stage 2 hypertension (sBP ≥160 mm Hg 
or dBP ≥110 mm Hg, or both). We classified women according to the maximum blood pressure category reached 
across all visits for the primary analyses. The primary outcome was a maternal, fetal, or neonatal mortality or 
morbidity composite. We estimated dose-response relationships between blood pressure category and adverse 
outcomes, as well as diagnostic test properties.
Findings Between Nov 1, 2014, and Feb 28, 2017, 21 069 women (6067 in India, 4163 in Mozambique, and 10 839 in 
Pakistan) contributed 103 679 blood pressure measurements across the three CLIP trials. Only women with non-
severe or severe stage 2 hypertension, as discrete diagnostic categories, experienced more adverse outcomes than 
women with normal blood pressure (risk ratios 1·29–5·88). Using blood pressure categories as diagnostic 
thresholds (women with blood pressure within the category or any higher category vs those with blood pressure 
in any lower category), dose-response relationships were observed between increasing thresholds and adverse 
outcomes, but likelihood ratios were informative only for severe stage 2 hypertension and maternal CNS events 
(likelihood ratio 6·36 [95% CI 3·65–11·07]) and perinatal death (5·07 [3·64–7·07]), particularly stillbirth (8·53 
[5·63–12·92]).
Interpretation In low-resource settings, neither elevated blood pressure nor stage 1 hypertension were associated 
with maternal, fetal, or neonatal mortality or morbidity adverse composite outcomes. Only the threshold for severe 
stage 2 hypertension met diagnostic test performance standards. Current diagnostic thresholds for hypertension in 
pregnancy should be retained.
Funding University of British Columbia, the Bill & Melinda Gates Foundation.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Hypertension in pregnancy has traditionally been 
defined as a systolic blood pressure (sBP) of at least 
140 mm Hg or a diastolic blood pressure (dBP) of at least 
90 mm Hg, or both.1 Hypertension defined in this 
way identifies pregnant women at increased risk of 
pre-eclampsia and other maternal and fetal or neonatal 
complications, including death, and these women are 
recommended to receive enhanced antenatal care and 
monitoring worldwide.
In 2017, the American College of Cardiology and 
American Heart Association recommended lowering 
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the blood pressure thresholds for diagnosing hyper-
tension outside of pregnancy, classified as: elevated 
blood pressure (or elevated sBP; defined as sBP 
120–129 mm Hg and dBP <80 mm Hg), stage 1 hyper-
tension (sBP 130–139 mm Hg or dBP 80–89 mm Hg, or 
both), and stage 2 hypertension (sBP ≥140 mm Hg or 
dBP ≥90 mm Hg, or both).2 Although the American 
College of Obstetricians and Gynecologists and 
WHO have retained a definition of blood pressure 
greater than or equal to 140/90 mm Hg for hypertension 
in pregnancy, several studies have reported a dose-
response relationship between increasing blood pressure 
and adverse pregnancy outcomes, across gestational 
ages;3,4 these findings provide potential support for the 
redefinition of hypertension in pregnancy. However, 
despite use of blood pressure as an essential screening 
test in pregnancy, no studies have yet reported the 
diagnostic test properties (such as sensitivity and 
specificity) of various blood pressure thresholds for 
hypertension diagnosis.
We aimed to analyse the relationship between blood 
pressure thresholds to define hypertension in pregnancy 
and adverse maternal, fetal, or neonatal outcomes, as 
well as the diagnostic test properties of these cutoffs, in 
low-resource settings.
Methods
Study design and participants
We did a secondary analysis of data from 22 interven-
tion clusters in the Community-Level Interventions 
for Pre-eclampsia (CLIP) cluster randomised trials 
(NCT01911494) in India (n=6), Mozambique (n=6), and 
Pakistan (n=10).5–8 The unit of randomisation (cluster) 
was the local administrative unit. We included pregnant 
women aged 15–49 years (12–49 years in Mozambique), 
identified in their community by trained community 
health workers, who had data on blood pressure 
measurements and outcomes. All women provided 
written informed consent to participate. The trial was 
unmasked given the nature of the intervention, aimed at 
addressing the so-called three delays in triage, transport, 
and treatment related to mortality risk, particularly 
associated with pre-eclampsia.9
Ethics approvals were granted by the University 
of British Columbia, Canada (H12-03497) and relevant in-
country research ethics boards (Aga Khan University, 
Pakistan, 2590-Obs-ERC-13; KLE University, India, 
MDC/IECHSR/2011-12/A-4, ICMR 5/7/859/12-RHN; 
Centro de Investigação em Saúde de Manhiça, 
Mozambique, CIBS-CISM/038/14; and Mozambique 
National Bioethic Committee, 219/CNBS/14).
Research in context
Evidence before this study
We searched MEDLINE, PubMed, Embase, CINAHL, CNTRAL, 
LILACS, Web of Science, and Google Scholar databases, 
including reference lists of eligible studies, for studies 
published in English between Jan 1, 2017, and Dec 31, 2020, 
using the search terms “human” AND (“hypertension” OR 
“hypertensive disorders of pregnancy” OR “pregnancy-induced 
hypertension” OR “preeclampsia” OR “pregnancy toxemias” 
OR “gestational hypertension”) AND (“American College of 
Cardiology” OR “American Heart Association”) AND (“stage 1 
hypertension” OR “prehypertension”) AND (“Pregnancy[mh]” 
OR “Pregnan*” OR “Gestation*” OR “pregnant women[mh]” 
OR “Pregnancy Complications[mh]” OR “Postpartum 
Period”[Mesh] OR “Puerperium” OR “postpartum” OR 
“Peripartum Period”[Mesh] OR “Peripartum*” OR “Perinatal 
Care[mh]” OR “perinatal”).
In 2017, the American College of Cardiology and American 
Heart Association recommended lowering blood pressure 
thresholds for diagnosing hypertension outside of pregnancy. 
Several studies have examined the risk of adverse pregnancy 
outcomes associated with these lower blood pressure values 
in pregnancy, compared with the established cutoff of 
140/90 mm Hg or greater.
Added value of this study
Nearly all evidence for using the American College of 
Cardiology and American Heart Association thresholds to 
diagnose hypertension in pregnancy are from high-income 
settings and rely on retrospective, routinely collected clinical 
data. Furthermore, these studies have focused exclusively on 
associative measures (such as risk ratios) between blood 
pressure thresholds and adverse outcomes. By contrast, this 
study provides prospective blood pressure data from more 
than 20 000 pregnant women, in three low-income and 
middle-income countries (LMICs), using standardised 
measurement technique and a validated device, and examines 
not only associations between blood pressure thresholds and 
adverse outcomes, but also the diagnostic test properties of 
those thresholds. Associations were dependent on blood 
pressure greater than or equal to 160/110 mm Hg.
Implications of all the available evidence
Our findings suggest that there is an association between the 
American College of Cardiology and American Heart 
Association blood pressure thresholds and adverse pregnancy 
outcomes in LMIC settings, but there is no antenatal blood 
pressure threshold that is sensitive with regards to the adverse 
maternal, fetal, or neonatal outcomes studied, including data-
driven cutoffs. However, severe stage 2 hypertension (blood 
pressure ≥160/110 mm Hg) is associated with a substantially 
increased risk of adverse maternal CNS outcomes and fetal or 
neonatal death, particularly stillbirth, and should be treated as 
per international guidance. Antenatal care must aim to provide 
more than accurate blood pressure measurement to achieve the 
Countdown 2030 goals.
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Procedures
First, community engagement addressed barriers and 
facilitators to accessing care. Second, existing cadres of 
community health workers were trained to task-share 
pregnancy hypertension-oriented care at CLIP contacts 
in women’s homes, using the CLIP Pre-eclampsia 
Integrated Estimate of Risk Score (PIERS) On-the-
Move (POM) digital health app for risk stratification.10 
Community health workers responded to emergency 
conditions (if applicable); measured women’s blood 
pressure and did dipstick urinalysis for proteinuria at 
the first and any subsequent contact where hypertension 
was identified; administered oral methyldopa (750 mg) 
if blood pressure was greater than or equal to 
160/110 mm Hg and intramuscular magnesium sulphate 
(10 g) if severe pre-eclampsia (defined as at least one 
of: sBP ≥160 mm Hg, mini pre-eclampsia integrated 
estimate of risk [miniPIERS] probability ≥25%, eclamp-
sia, or stroke) was suspected; and referred women 
to a comprehensive emergency obstetric care facility 
if advised by POM. Antenatal POM-guided visits 
(including blood pressure measurement) were scheduled 
monthly from enrolment.
Blood pressure measurement for all women in the 
intervention clusters (and, therefore, in this analysis) 
was standardised and taken by trained community 
health workers, using a semi-automated pregnancy-
validated and pre-eclampsia-validated oscillometric 
device (Microlife 3AS1-2; Microlife, Taipei, Taiwan).11 
Women were instructed to rest for 5 min, then their 
blood pressure was measured at least twice, with a third 
measurement taken if the first two readings differed by 
10 mmHg or more. All readings were entered into the 
POM app, with blood pressure for the visit calculated as 
the mean of the first two readings, or of the second and 
third if three readings were taken. All readings were 
stored electronically in REDCap databases.
Trained surveillance teams did regular household 
surveys (every 3–6 months) in Mozambique and Pakistan; 
in India, a prospective population-based surveillance 
system was established. The PRE-eclampsia Eclampsia 
Monitoring, Prevention, and Treatment (PRE-EMPT) 
research group, University of British Columbia, Canada, 
was responsible for overall trial coordination and data 
management.
Outcomes
The primary CLIP composite outcome was a composite 
of maternal, fetal, and neonatal mortality and morbidity, 
and all outcomes were adjudicated by an in-country 
team of clinicians. Maternal death and morbidity were 
assessed during pregnancy or within 42 days after 
pregnancy; morbidity was defined as one or more life-
threatening pregnancy complications (a serious end-
organ compli cation of pre-eclampsia [ie, eclampsia, 
stroke, coma, antepartum haemorrhage, or disseminated 
intravascular coagulation], another major maternal 
complication [ie, obstetric sepsis, or vesicovaginal 
or rectovaginal fistula], or receipt of a life-saving inter-
vention [ie, cardiopulmonary resuscitation, mechanical 
ventilation, blood transfusion, interventions for major 
post-partum haemorrhage, or dialysis]). This analysis 
also included a maternal CNS composite outcome of 
one or more of maternal eclampsia, stroke, coma, or 
mortality. Fetal or neonatal death included stillbirth, 
Participants (n=21 069)
Country 
India 6067 (28·8%) 
Mozambique 4163 (19·8%) 
Pakistan 10 839 (51·4%) 
Maternal age, years 25·0 (22·0–30·0)
Maternal basic level of education* 8409 (39·9%) 
Gestational age at enrolment, weeks 17·1 (11·2–24·1)
Enrolment at ≥20 weeks of gestation 7832 (37·2%) 
Parous 15 099 (71·7%) 
Blood pressure, mm Hg
Mean sBP 106·0 (100·4–112·0)
Mean dBP 66·6 (62·5–71·0)
Maximum sBP 113·0 (106·0–120·0)
Maximum dBP 73·0 (67·0–79·0)
Maximal blood pressure category† 
Normal blood pressure 13 780 (65·4%) 
Elevated blood pressure 2196 (10·4%) 
Stage 1 hypertension 3751 (17·8%) 
Non-severe stage 2 hypertension 1178 (5·6%) 
Severe stage 2 hypertension 164 (0·8%) 
Gestational age at delivery, weeks 39·0 (37·0–40·4)
Preterm delivery (<37 weeks of gestation) 4651 (22·1%)
Outcomes‡ 
Primary CLIP composite 4816 (22·9%) 
Maternal mortality 43 (0·2%) 
Maternal morbidity 2006 (9·5%) 
Maternal CNS composite 282 (1·3%) 
Fetal or neonatal death 1657 (7·9%) 
Stillbirth 810 (3·8%)
Data are n (%) or median (IQR) unless otherwise stated. sBP=systolic blood 
pressure. dBP=diastolic blood pressure. CLIP=Community-Level Interventions for 
Pre-eclampsia. *Basic level of education was defined as at least 8 years of 
schooling in India, at least attainment of grade 5 in Mozambique, or at least 
5 years of schooling in Pakistan. †Blood pressure was categorised as: normal blood 
pressure (sBP <120 mm Hg and dBP <80 mm Hg), elevated blood pressure 
(sBP 120–129 mm Hg and dBP <80 mm Hg), stage 1 hypertension 
(sBP 130–139 mm Hg or dBP 80–89 mm Hg, or both), non-severe stage 2 
hypertension (sBP 140–159 mm Hg or dBP 90–109 mm Hg, or both), or severe 
stage 2 hypertension (sBP ≥160 mm Hg or dBP ≥110 mm Hg, or both). 
‡The primary CLIP composite outcome was a composite of maternal and perinatal 
mortality and morbidity. Maternal mortality or morbidity were assessed during 
pregnancy or within 42 days after pregnancy; morbidity was defined as one or 
more life-threatening pregnancy complications (ie, a serious end-organ 
complication of pre-eclampsia, another major cause of maternal mortality, or 
receipt of a life-saving intervention). The maternal CNS composite outcome was 
one or more of maternal eclampsia, stroke, coma, or mortality. Fetal or neonatal 
death included stillbirth and early or late neonatal mortality (appendix p 4).
Table 1: Baseline characteristics
Articles
e1122 www.thelancet.com/lancetgh   Vol 9   August 2021
early neonatal mortality, or late neonatal mortality 
(appendix p 4).
In this analysis, we included CLIP trial participants 
who were from intervention groups and had at least one 
POM app-guided antenatal contact with blood pressure 
measurement done by community health workers at a 
clinically estimated gestation of 44 weeks or less. 
Analyses including post-partum and perinatal outcomes 
were restricted to women who had delivered and provided 
outcome information.
We classified the antenatal blood pressure readings for 
each woman at each visit, on the basis of the American 
College of Cardiology and American Heart Association 
criteria,2 as: normal blood pressure (sBP <120 mm Hg 
and dBP <80 mm Hg), elevated blood pressure (sBP 
120–129 mm Hg and dBP <80 mm Hg), stage 1 hyper-
tension (sBP 130–139 mm Hg or dBP 80–89 mm Hg, 
or both), non-severe stage 2 hypertension (sBP 
140–159 mm Hg or dBP 90–109 mm Hg, or both), and 
severe stage 2 hypertension (sBP ≥160 mm Hg or dBP 
≥110 mm Hg, or both). We classified women according to 
the maximum blood pressure category reached across all 
visits for the primary analyses. Women who were 
hypertensive before 20 weeks of gestation were regarded 
as having chronic hypertension, and those who were 
hypertensive at 20 weeks of gestation or greater were 
regarded as having gestational hypertension or pre-
eclampsia.12
Statistical analysis
Descriptive statistics were used to summarise baseline 
maternal characteristics, and maximal blood pressure 
categories overall and according to gestational age at 
measurement (<20 weeks vs ≥20 weeks).
The possible dose-response relationship between 
blood pressure category and adverse outcomes was 
assessed in two ways. First, we treated each category as 
mutually exclusive and calculated the risk ratio (RR) 
between normal blood pressure and each category, 
using generalised estimating equations with a Poisson 
link function.13 Second, we fit analogous models, but 
treated the lower limit of each category as a blood 
pressure cutoff for diagnosis of hypertension. For 
example, for stage 1 hypertension, we compared women 
with sBP 130 mm Hg or greater or dBP 80 mm Hg or 
greater (or both), with those who had sBP less than 
130 mm Hg and dBP less than 80 mm Hg. All models 
were adjusted for maternal age, maternal basic level of 
education (ie, ≥8 years of schooling in India, attainment 
of at least grade 5 in Mozambique, or ≥5 years of 
Figure 1: Maximal blood pressure measurements by gestational age
Maximal blood pressure values per woman are shown, as a median with IQR for each gestational age week.
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schooling in Pakistan), gestational age at enrolment, 
and nulliparity. SEs were based on the sandwich 
estimator to account for clustering.
The diagnostic test properties of blood pressure 
categories were assessed using sensitivity, specificity, 
and positive and negative likelihood ratios (LRs). 
Positive LR was calculated as: sensitivity / (1 – specificity). 
Negative LR was calculated as: (1 – sensitivity) / specificity. 
CIs were calculated by standard methods.14 For each 
calculation, women with blood pressure equal to or 
higher than the given blood pressure threshold were 
compared with those with blood pressure lower than the 
threshold. LRs describe the likelihood that a given test 
result would alter the probability of a diagnosis; positive 
LR values were interpreted as good if greater than or 
equal to 5·0 and negative LR values were interpreted as 
good if less than 0·2.
In a sensitivity analysis to determine if the sensitivity of 
blood pressure categories for adverse outcomes improved 
closer to term, we re-classified women according to 
the maximum blood pressure category reached within 
predefined gestational age categories (28 weeks to 
<32 weeks, 32 weeks to <37 weeks, and ≥37 weeks of 
gestation). Also, we estimated the optimal sBP and dBP 
cutoffs to maximise sensitivity of blood pressure for fixed 
false-positive rates of 5%, 10%, and 20%. All analyses 
were done using R version 4.0.2.15
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
Between Nov 1, 2014, and Feb 28, 2017, 21 069 women 
(6067 in India, 4163 in Mozambique, and 10 839 in 
Pakistan) contributed 103 679 blood pressure measure-
ments across the three CLIP trials (table 1). Most women 
were aged in their mid-20s, had less than a basic level 
of education, and were parous. In general, women 
were enrolled in CLIP late in the first trimester or early 
in the second trimester, with most enrolling at less 
than 20 weeks of gestation. About two-thirds of women 
had normal blood pressure throughout pregnancy. 
Slightly more than one-quarter of women had abnormal 
blood pressure classified as elevated blood pressure 
(2196 [10·4%] of 21 069) or non-severe stage 1 hyperten-
sion (3751 [17·8%]). Stage 2 hypertension (non-severe or 
severe) occurred in 1342 (6·4%) of 21 069 women. Most 
women delivered at term, but one-quarter delivered 
preterm. Another quarter suffered a maternal, fetal, or 
neonatal complication, which were mostly morbidity 
for the mother (about one in ten women) or death of 
the fetus (42 per 1000 livebirths) or neonate (41 per 1000 
livebirths). Blood pressure was only 1–2 mmHg higher 
among women with adverse outcomes than in women 
without adverse outcomes (appendix p 5).
Blood pressure values overall were stable, without a 
clinically important mid-trimester decrease, until about 
30 weeks of gestation, after which both sBP and dBP 
increased with advancing gestational age (figure 1). 
Maximal blood pressure values classified as elevated 
blood pressure, stage 1 hypertension, and stage 2 hyper-
tension (non-severe or severe) were more common 
with advancing gestational age (figure 2). Blood 
pressure in most women remained at the same category 
or decreased after 20 weeks of gestation or longer, 
regardless of whether blood pressure at less than 
20 weeks of gestation was classified as normal blood 
pressure (5160 [63·0%] of 8194 women), elevated blood 
pressure (336 [60·8%] of 552), stage 1 hyper tension 
(527 [75·7%] of 696), or non-severe stage 2 hyper-
tension (91 [75·8%] of 120; table 2). If the stage 1 
hypertension category cutoffs were used as the new 
threshold for diagnosing hypertension in pregnancy, an 
additional 1681 (17·5%) of 9574 women would be 
diagnosed; if elevated blood pressure category cutoffs 
were used, an additional 1021 (10·7%) of women would 
be diagnosed (table 2).
There was a dose-response relationship between 




Non-severe stage 2 hypertension
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Gestational age at measurement (weeks)
Figure 2: Maximal blood pressure measurements as blood pressure categories by gestational age
A log-scale is used for the y-axis (number of women) for clarity. Blood pressure was categorised as: normal blood 
pressure (sBP <120 mm Hg and dBP <80 mm Hg), elevated blood pressure (sBP 120–129 mm Hg and 
dBP <80 mm Hg), stage 1 hypertension (sBP 130–139 mm Hg or dBP 80–89 mm Hg, or both), non-severe stage 2 
hypertension (sBP 140–159 mm Hg or dBP 90–109 mm Hg, or both), or severe stage 2 hypertension 
(sBP ≥160 mm Hg or dBP ≥110 mm Hg, or both).
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adverse outcomes compared with normal blood 
pressure, for most outcomes with non-severe stage 2 
hypertension and for all outcomes with severe stage 2 
hypertension, which increased risk by at least two times 
and up to six times (table 3). When the diagnostic 
criteria for each blood pressure category were used as a 
threshold for diagnosis of an abnormal blood pressure, 
the risk of all adverse outcomes, other than the maternal 
composite, increased from elevated blood pressure 
onwards; however, the point estimates for elevated 
blood pressure, stage 1 hypertension, and non-severe 
stage 2 hyper tension were consistently higher than they 
were when these blood pressure categories were each 
compared with normal blood pressure, and RRs were 
less than 2·00 for all but non-severe stage 2 hypertension 
and stillbirth.
The only blood pressure category that was useful as a 
diagnostic test for the outcomes examined was severe 
stage 2 hypertension; sensitivity was low, but the positive 
LR was good for the maternal CNS composite outcome 
and fetal or neonatal death, particularly stillbirth (table 4). 
All other blood pressure categories, including non-severe 
stage 2 hypertension, had low sensitivity (<45%) for all 
outcomes, and uninformative positive LR and negative 
LR values.
In sensitivity analyses restricted to blood pressure 
measurements in specific gestational age ranges within 
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Normal blood pressure at <20 weeks (n=8194) 5160 685* 1035*† 378 48 888
Elevated blood pressure at <20 weeks (n=552) 219* 117* 119*† 49 0 48
Stage 1 hypertension at <20 weeks (n=696) 206*† 87*† 234*† 83 11 75
Non-severe stage 2 hypertension at <20 weeks (n=120) 27 7 36 21 13 16
Severe stage 2 hypertension at <20 weeks (n=12) 2 1 1 3 2 3
No blood pressure values at <20 weeks (n=11 495) 7732 1127 1995 561 80 0
Data are n. Blood pressure was categorised as: normal blood pressure (sBP <120 mm Hg and dBP <80 mm Hg), elevated blood pressure (sBP 120–129 mm Hg and 
dBP <80 mm Hg), stage 1 hypertension (sBP 130–139 mm Hg or dBP 80–89 mm Hg, or both), non-severe stage 2 hypertension (sBP 140–159 mm Hg or dBP 90–109 mm Hg, 
or both), or severe stage 2 hypertension (sBP ≥160 mm Hg or dBP ≥110 mm Hg, or both). sBP=systolic blood pressure. dBP=diastolic blood pressure. *Indicates women who 
would additionally be diagnosed with hypertension if elevated blood pressure was used as the threshold for diagnosing hypertension in pregnancy. †Indicates women 
who would additionally be diagnosed with hypertension if stage 1 hypertension was used as the threshold for diagnosing hypertension in pregnancy.





Stage 1 hypertension Non-severe stage 2 
hypertension
Severe stage 2 
hypertension
Comparison with normal blood pressure category
CLIP composite 1 (ref) 0·99 (0·94–1·03) 1·08 (1·00–1·16)*† 1·29 (1·13–1·47)† 2·48 (2·06–2·98)†
Maternal composite 1 (ref) 1·02 (0·89–1·17) 1·11 (0·93–1·33) 1·20 (0·90–1·59) 2·40 (1·60–3·59)†
Maternal CNS composite 1 (ref) 0·98 (0·63–1·51) 1·26 (0·91–1·75) 1·46 (1·00–2·13)† 6·05 (3·88–9·46)†
Fetal or neonatal death 1 (ref) 0·93 (0·79–1·09) 1·15 (0·96–1·38) 1·48 (1·10–1·97)† 4·09 (3·02–5·55)†
Stillbirth 1 (ref) 0·98 (0·74–1·29) 1·24 (0·97–1·58) 1·81 (1·30–2·54)† 5·88 (3·95–8·73)†
Comparison of blood pressure category and all higher categories, with all lower blood pressure categories‡
CLIP composite ·· 1·12 (1·05–1·19)† 1·17 (1·09–1·26)† 1·41 (1·24–1·60)† 2·48(2·06–2·98)†
Maternal composite ·· 1·13 (0·96–1·33) 1·17 (0·98–1·40) 1·32 (1·05–1·65)† 2·40 (1·60–3·59)†
Maternal CNS composite ·· 1·32 (1·08–1·61)† 1·47 (1·13–1·90)† 1·91 (1·41–2·57)† 6·05 (3·88–9·46)†
Fetal or neonatal death ·· 1·20 (1·02–1·43)† 1·33 (1·12–1·58)† 1·75 (1·42–2·15)† 4·09 (3·02–5·55)†
Stillbirth ·· 1·36 (1·09–1·70)† 1·52 (1·24–1·87)† 2·19 (1·72–2·79)† 5·88 (3·95–8·73)†
Data are RR (95% CI). Blood pressure was categorised as: normal blood pressure (sBP <120 mm Hg and dBP <80 mm Hg), elevated blood pressure (sBP 120–129 mm Hg and 
dBP <80 mm Hg), stage 1 hypertension (sBP 130–139 mm Hg or dBP 80–89 mm Hg, or both), non-severe stage 2 hypertension (sBP 140–159 mm Hg or dBP 90–109 mm Hg, 
or both), or severe stage 2 hypertension (sBP ≥160 mm Hg or dBP ≥110 mm Hg, or both). RRs were estimated from modified Poisson and adjusted for maternal age, maternal 
basic education, gestational age at enrolment, and nulliparity. For outcome definitions, see the appendix (pp 3–4). RR=risk ratio. CLIP=Community-Level Interventions for 
Pre-eclampsia. sBP=systolic blood pressure. dBP=diastolic blood pressure. *Unrounded lower limit of 95% CI is 1·002. †95% CI does not overlap 1. ‡For example, for stage 1 
hypertension, the comparison is for all women with sBP 130 mm Hg or greater or dBP 80 mm Hg or greater, or both, versus all women with sBP <130 mm Hg and 
dBP <80 mm Hg; the exception to this approach was for the normal blood pressure category which was compared with all higher blood pressure categories.
Table 3: Adjusted RRs for blood pressure categories and adverse outcomes
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blood pressure categories, including the elevated blood 
pressure category, although sensitivity was slightly 
higher for measurements from 32 weeks to less than 
37 weeks (appendix p 8). Also, sensitivity remained 
low (<20%) for optimal sBP (123–136 mm Hg) and 
dBP (81–104 mm Hg) cutoffs, for fixed false-positive 
rates of 5%, 10%, and 20% (appendix p 6).
Discussion
In the CLIP trial clusters in low-resource settings, 
women classified as having elevated blood pressure or 
stage 1 hypertension did not have an increased risk 
of adverse maternal, fetal, or neonatal outcomes com-
pared with women with normal blood pressure 
(<120/80 mm Hg). Risk of adverse outcomes was 
increased with stage 2 hypertension, particularly with 
severe stage 2 hypertension, which was associated with a 
two to six times increased risk compared with normal 
blood pressure. When blood pressure categories higher 
than normal were used as diagnostic cutoffs for abnormal 
blood pressure (how 140/90 mm Hg is currently used), 
the risk of adverse outcomes was increased; however, this 
increase was driven by the risks associated with severe 
stage 2 hypertension. In addition, sensitivities for adverse 
outcomes were low (<45%), and no category other than 
severe stage 2 hypertension showed useful diagnostic 
test properties. Using optimal cutpoint analyses for false-
positive rates considered clinically reasonable led to poor 
sensitivity (<30%) for all outcomes.
If elevated blood pressure was used as a diagnostic 
cutoff, an additional 28% of women would be labelled 
as having an abnormal blood pressure; if stage 1 
Events, n (%)* Sensitivity (95% CI) Specificity (95% CI) Positive LR (95% CI)† Negative LR (95% CI)‡
CLIP composite
Normal blood pressure (n=13 441) 2987 (22·2%) ·· ·· ·· ··
Elevated blood pressure (n=2149) 484 (22·5%) 38·0% (36·6–39·4) 66·3% (65·5–67·0) 1·13 (1·08–1·17) 0·94 (0·91–0·96)
Stage 1 hypertension (n=3679) 937 (25·5%) 27·9% (26·7–29·2) 76·8% (76·1–77·5) 1·20 (1·14–1·27) 0·94 (0·92–0·96)
Non-severe stage 2 hypertension (n=1163) 321 (27·6%) 8·5% (7·7–9·0) 94·2% (93·8–94·6) 1·46 (1·30–1·63) 0·97 (0·96–0·98)
Severe stage 2 hypertension (n=161) 87 (54·0%) 1·8% (1·4–2·2) 99·5% (99·4–99·6) 3·85 (2·83–5·24) 0·99 (0·98–0·99)
Maternal composite
Normal blood pressure (n=13 424) 1253 (9·3%) ·· ·· ·· ··
Elevated blood pressure (n=2146) 212 (9·9%) 38·2% (36·1–40·4) 65·7% (65·0–66·3) 1·11 (1·05–1·18) 0·94 (0·91–0·97)
Stage 1 hypertension (n=3674) 409 (11·1%) 27·8% (25·9–29·8) 76·1% (75·5–76·7) 1·16 (1·08–1·25) 0·95 (0·92–0·98)
Non-severe stage 2 hypertension (n=1163) 120 (10·3%) 7·6% (6·5–8·9) 93·7% (93·3–94·0) 1·21 (1·03–1·42) 0·99 (0·97–1·00)
Severe stage 2 hypertension (n=160) 35 (21·9%) 1·7% (1·2–2·4) 99·3% (99·2–99·4) 2·56 (1·76–3·71) 0·99 (0·98–1·00)
Maternal CNS composite
Normal blood pressure (n=13 413) 161 (1·2%) ·· ·· ·· ··
Elevated blood pressure (n=2145) 29 (1·4%) 42·9% (37·1–48·9) 65·4% (64·7–66·0) 1·24 (1·08–1·42) 0·87 (0·79–0·97)
Stage 1 hypertension (n=3671) 56 (1·5%) 32·6% (27·2–38·4) 75·8% (75·2–76·4) 1·35 (1·14–1·60) 0·89 (0·82–0·96)
Non-severe stage 2 hypertension (n=1163) 23 (2·0%) 12·8% (9·1–17·2) 93·7% (93·3–94·0) 2·01 (1·48–2·74) 0·93 (0·89–0·97)
Severe stage 2 hypertension (n=160) 13 (8·1%) 4·6% (2·5–7·8) 99·3% (99·1–99·4) 6·36 (3·65–11·07) 0·96 (0·94–0·99)
Fetal or neonatal death
Normal blood pressure (n=12 902) 985 (7·6%) ·· ·· ·· ··
Elevated blood pressure (n=2126) 155 (7·3%) 40·6% (38·2–43·0) 65·0% (64·3–65·7) 1·16 (1·09–1·23) 0·91 (0·88–0·95)
Stage 1 hypertension (n=3647) 337 (9·2%) 31·2% (29·0–33·5) 75·8% (75·1–76·4) 1·29 (1·19–1·39) 0·91 (0·88–0·94)
Non-severe stage 2 hypertension (n=1155) 130 (11·3%) 10·9% (9·4–12·5) 93·8% (93·5–94·2) 1·76 (1·51–2·04) 0·95 (0·93–0·97)
Severe stage 2 hypertension (n=159) 50 (31·4%) 3·0% (2·2–4·0) 99·4% (99·3–99·5) 5·07 (3·64–7·07) 0·98 (0·97–0·98)
Stillbirth
Normal blood pressure (n=12 468) 457 (3·7%) ·· ·· ·· ··
Elevated blood pressure (n=2066) 77 (3·7%) 43·6% (40·1–47·1) 65·0% (64·3–65·7) 1·24 (1·15–1·35) 0·87 (0·82–0·92)
Stage 1 hypertension (n=3496) 167 (4·8%) 34·1% (30·8–37·5) 76·2% (75·4–76·9) 1·43 (1·29–1·58) 0·87 (0·82–0·91)
Non-severe stage 2 hypertension (n=1112) 76 (6·8%) 13·5% (11·2–16·0) 94·8% (94·4–95·2) 2·59 (2·14–3·13) 0·91 (0·89–0·94)
Severe stage 2 hypertension (n=151) 33 (21·9%) 4·1% (2·8–5·7) 99·5% (99·4–99·6) 8·53 (5·63–12·92) 0·96 (0·95–0·98)
Diagnostic test properties are calculated for women with blood pressure at each threshold or higher (compared with women with blood pressure below that threshold, based 
on cumulative rates). For outcome definitions, see the appendix (pp 3–4). Blood pressure was categorised as: normal blood pressure (sBP <120 mm Hg and dBP <80 mm Hg), 
elevated blood pressure (sBP 120–129 mm Hg and dBP <80 mm Hg), stage 1 hypertension (sBP 130–139 mm Hg or dBP 80–89 mm Hg, or both), non-severe stage 2 
hypertension (sBP 140–159 mm Hg or dBP 90–109 mm Hg, or both), or severe stage 2 hypertension (sBP ≥160 mm Hg or dBP ≥110 mm Hg, or both). LR=likelihood ratio. 
CLIP=Community-Level Interventions for Pre-eclampsia. sBP=systolic blood pressure. dBP=diastolic blood pressure. *Events only include women in the category specified; 
the denominator is women with complete outcome data. †A positive LR of 5·0 or greater was considered good. ‡A negative LR of less than 0·20 was considered good.
Table 4: Sensitivity, specificity, and LRs for adverse outcomes by American College of Cardiology and American Heart Association blood pressure categories
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hypertension was used, this would be an additional 
11% of women, in addition to women already identified 
as having hypertension by current criteria (ie, stage 2 
hypertension in this study). In our study population, the 
prevalence of hypertension was previously found to be 
14·0% in India, 16·8% in Mozambique, and 11·6% in 
Pakistan, after inclusion of hypertensive diagnoses from 
household survey and facility records.16 Therefore, an 
additional 28% or 11% of women with diagnoses of 
hypertension (depending on the cutoff used) would 
substantially increase the burden on health systems 
under stress, and could be justified only by the ability to 
identify women and babies at risk.
To our knowledge, this is the first study to report on 
the diagnostic properties of using revised blood 
pressure thresholds for the diagnosis of hypertension in 
pregnancy, and the first to report on outcomes by specific 
blood pressure thresholds for women in under-resourced 
settings.
Numerous studies have reported that women with 
antenatal elevated blood pressure or stage 1 hypertension 
by American College of Cardiology and American Heart 
Association criteria, as used in our analyses, have an 
increased risk of adverse pregnancy outcomes;3,4,17–19 
these included pre-eclampsia and other outcomes 
(eg, hospitalisation) not reported in our study. Many 
published RRs for adverse maternal and fetal or 
neonatal outcomes have been higher than in our study. 
It is possible that the relationship between blood 
pressure and adverse outcomes might be different in 
our study setting. Furthermore, we had fewer baseline 
character istics with which to adjust our RRs compared 
with other studies,4,17–20 and we studied unselected 
pregnant women, not just those who were nulliparous21,22 
or primarily nulliparous.23 Alternatively, the differences 
in RRs might have been due to methodology. Our 
data collection was prospective and blood pressure 
measurement was standardised, using a device validated 
for pregnancy and pre-eclampsia.11 By contrast, most 
published data have been retrospective and from 
large urban referral centres with blood pressure 
measurements from routine clinical care.4,17–20,23 One 
prospective study restricted blood pressure observations 
to women at less than 20 weeks of gestation,21,22 by 
contrast to our blood pressure measurements that were 
done throughout pregnancy, the majority of which were 
done after 20 weeks of gestation. One prospective study 
in South Africa reported that, among 1116 women, an 
additional 37·1% would be classified as having abnormal 
blood pressure by the American College of Cardiology 
and American Heart Association criteria; although 
pregnancy outcomes were not reported separately 
for these women compared with those with stage 2 
hypertension,24 it has been reported among pregnant 
teenagers in the same setting that eclampsia might 
follow antenatal blood pressure values of less than 
140/90 mm Hg.25
Importantly, none of the aforementioned studies have 
reported the diagnostic test properties of various blood 
pressure categories to define abnormal blood pressure 
in pregnancy. As blood pressure measurement in 
pregnancy is a screening test, it should have high 
sensitivity for the adverse outcomes of interest, 
which can then lead to the established therapeutic 
care pathways for hypertension in pregnancy. However, 
blood pressure measurement is not sensitive, whether 
American College of Cardiology and American Heart 
Association categories are used (even elevated blood 
pressure) or an optimal blood pressure cutoff is 
estimated from the data and chosen. Perhaps this poor 
sensitivity is unsurprising, as the hypertensive disorders 
of pregnancy are one of three leading causes of adverse 
maternal outcomes (along with obstetric haemorrhage 
and sepsis), including spontaneous preterm birth, fetal 
growth restriction, and intrapartum complications for 
fetal or neonatal outcomes,26 and these other conditions 
could not be predicted by abnormal blood pressure. 
Nevertheless, although blood pressure measurement is 
regarded by WHO as good clinical practice that does not 
require evidence review,27 measurement is but one part 
of quality antenatal care and when normal, might 
provide minimal reassurance that adverse outcomes are 
less likely to occur.
The one blood pressure category that was useful in 
identifying women at increased risk of adverse outcomes 
(ie, maternal CNS outcomes and fetal or neonatal death) 
was severe stage 2 hypertension. This finding endorses 
severe stage 2 hypertension as a condition that should 
be avoided, as have previous data from well resourced 
settings,28 by contrast to regarding severe hypertension as 
a condition that can be treated if it occurs.29
Our study has several strengths, including our large 
sample size, community-based recruitment of unselected 
pregnant women in south Asia and sub-Saharan Africa, 
and the standardisation of blood pressure readings 
across the sample, using a pregnancy-validated device.11 
These factors help to provide evidence for hypertension 
diagnostic thresholds that is applicable to a large set of 
pregnant women in these settings.
This study has several limitations. First, many women 
in Pakistan and Mozambique were enrolled after 
20 weeks of gestation, consistent with timing of booking 
for antenatal care in these settings; therefore, a diagnosis 
of chronic hypertension could not be evaluated when 
blood pressure was measured after 20 weeks of gestation. 
Second, only basic maternal characteristics were avail-
able for our adjusted analyses. Third, many women did 
not have weekly blood pressure measurements from 
36 weeks of gestation to delivery as specified in the CLIP 
protocol, so although the household survey and facility 
records ultimately informed diagnoses of hypertension, 
we did not have all relevant blood pressure values for this 
analysis, particularly from close to term. Women with 
stage 2 hypertension, whether severe or non-severe, were 
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referred to facilities for antihypertensive treatment 
(about which we have no further information) and facility 
care; although not the focus of our analyses, such 
management is likely to have attenuated the relationship 
between stage 2 hypertension and outcomes and 
overestimated the strength of association between lower 
levels of blood pressure and adverse outcomes. Finally, 
we did not include in our analysis the outcome of pre-
eclampsia given our community setting, and so could 
not evaluate this as an outcome with the revised 
hypertension definitions embedded in it.
Pregnant women in under-resourced settings with 
higher-than-normal blood pressure are at increased risk 
of adverse outcomes, due to the risks associated with 
blood pressure of 140/90 mm Hg or higher, particularly 
with severe stage 2 hypertension. No antenatal blood 
pressure threshold is sensitive with regards to the adverse 
maternal, fetal, or neonatal outcomes studied, including 
data-driven cutoffs. However, the occurrence of severe 
stage 2 hypertension (≥160/110 mm Hg) is associated 
with a substantially increased risk of adverse maternal 
CNS outcomes and fetal or neonatal death, particularly 
stillbirth, and should be treated as per international 
guidance.30 Antenatal care must aim to provide more than 
accurate blood pressure measurement to achieve the 
Countdown 2030 goals.
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